Developing New Medicines for Tuberculosis
Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.
['FUNDING_R21'] · UNIVERSITY OF CENTRAL FLORIDA · NIH-11140519
This project is looking for new and better medicines to treat tuberculosis, a serious infection that affects many people worldwide.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CENTRAL FLORIDA (nih funded) |
| Locations | 1 site (ORLANDO, UNITED STATES) |
| Trial ID | NIH-11140519 on ClinicalTrials.gov |
What this research studies
Current treatments for tuberculosis (TB) can be long, lasting four months or more, and often come with difficult side effects. Many patients struggle to complete these regimens, and drug-resistant forms of TB are becoming a growing concern. This project aims to discover new types of antibiotics that can more effectively kill the bacteria causing TB, including those that hide in different parts of the body or are in various metabolic states. The goal is to find drugs that work better and faster, making treatment easier and more successful for patients.
Who could benefit from this research
Good fit: Patients currently suffering from tuberculosis, especially those with drug-resistant forms or those who struggle with current long-term treatments, could eventually benefit from this research.
Not a fit: Individuals who do not have tuberculosis would not directly benefit from this specific drug development effort.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective, and shorter treatments for tuberculosis, improving patient outcomes and reducing side effects.
How similar studies have performed: While current TB treatments exist, this project focuses on developing novel drug candidates to address the limitations and challenges, such as drug resistance and long treatment durations, that existing therapies face.
Where this research is happening
ORLANDO, UNITED STATES
- UNIVERSITY OF CENTRAL FLORIDA — ORLANDO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROHDE, KYLE H — UNIVERSITY OF CENTRAL FLORIDA
- Study coordinator: ROHDE, KYLE H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.